Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Kimia Farma Persero TbkISX:KAEF +0.46%55 Debt-to-EBITDA is 10.60 as of Jun. 2026, which is 89% above its 10-year median of 5.61. GuruFocus rates ISX:KAEF with a GF Score™ of 55/100 and a GF Value™ of Rp579.89 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 91 Medical Distribution companies, PT Kimia Farma Persero Tbk ranks worse than 90.11% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for PT Kimia Farma Persero Tbk's Debt-to-EBITDA or its related term are showing as below:
ISX:KAEF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -41.45 Med: 5.61 Max: 13
Current: 9.75
During the past 13 years, the highest Debt-to-EBITDA Ratio of PT Kimia Farma Persero Tbk was 13.00. The lowest was -41.45. And the median was 5.61.
ISX:KAEF's Debt-to-EBITDA is ranked worse than 90.11% of 91
companies
in the Medical Distribution industry
Industry Median: 2.29
vs ISX:KAEF: 9.75
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
PT Kimia Farma Persero Tbk Debt-to-EBITDA Related Terms
PT Kimia Farma Persero Tbk Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:KAEF vs MCK, COR, CAH: Debt-to-EBITDA Comparison
For the Medical Distribution subindustry, PT Kimia Farma Persero Tbk's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Kimia Farma Persero Tbk Debt-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, PT Kimia Farma Persero Tbk's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PT Kimia Farma Persero Tbk's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
PT Kimia Farma Persero Tbk (ISX:KAEF) has a Debt-to-EBITDA of 10.60 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PT Kimia Farma Persero Tbk. This is 89% above median its historical median of 5.61. According to the industry distribution chart, PT Kimia Farma Persero Tbk ranks #82 out of 91 companies in the Medical Distribution industry, placing it in the top 90.1%.
Is PT Kimia Farma Persero Tbk's Debt-to-EBITDA too high?
PT Kimia Farma Persero Tbk's current Debt-to-EBITDA of 10.60 is 89% above median its 10-year median of 5.61. The Medical Distribution industry median Debt-to-EBITDA is 2.29. PT Kimia Farma Persero Tbk's value of 10.60 is 362.9% above this industry median. Based on the distribution chart, PT Kimia Farma Persero Tbk ranks #82 out of 91 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, PT Kimia Farma Persero Tbk has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kimia Farma Persero Tbk's Debt-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, PT Kimia Farma Persero Tbk ranks #82 out of 91 companies for Debt-to-EBITDA. This places PT Kimia Farma Persero Tbk in the lower half of its industry. The industry median Debt-to-EBITDA is 2.29. PT Kimia Farma Persero Tbk's value of 10.60 is 362.9% above this benchmark. While the company's 10-year median is 5.61 vs. the industry median of 2.29, PT Kimia Farma Persero Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Distribution company?
The median Debt-to-EBITDA among Medical Distribution companies is 2.29, based on 91 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Kimia Farma Persero Tbk's current Debt-to-EBITDA of 10.60 is 362.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PT Kimia Farma Persero Tbk. For the Medical Distribution industry, the median Debt-to-EBITDA is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Kimia Farma Persero Tbk's current Debt-to-EBITDA is 10.60, which is 89% above median its own 10-year median of 5.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kimia Farma Persero Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kimia Farma Persero Tbk (ISX:KAEF) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp579.89, compared to a current price of Rp440.00 — trading 24.1% below its estimated fair value. The current Debt-to-EBITDA is 10.60, which is 89% above median its 10-year median of 5.61 and 362.9% above the Medical Distribution industry median of 2.29. PT Kimia Farma Persero Tbk's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For PT Kimia Farma Persero Tbk (ISX:KAEF), the current Debt-to-EBITDA is 10.60 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Kimia Farma Persero Tbk (ISX:KAEF) Overvalued in 2026?
Based on GuruFocus' analysis, PT Kimia Farma Persero Tbk stock appears to be undervalued.
The current stock price of Rp440.00 is trading 24.1% below its estimated GF Value™ of Rp579.89.
GuruFocus considers PT Kimia Farma Persero Tbk to be Modestly Undervalued.
Key valuation signals for ISX:KAEF:
Debt-to-EBITDA: 10.60 (89% above median its 10-year median of 5.61)
GF Value™: Rp579.89 vs. price of Rp440.00 (24.1% below fair value)
Industry Position: 362.9% above the Medical Distribution median (#82 of 91)
No single metric tells the full story. See the ISX:KAEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Kimia Farma Tbk is an Indonesia-based company engaged in the production and distribution of healthcare products. It operates through the following segments: Manufacture, Distribution, Retail, and Others. The company provides its products in categories including OTC & Herb, Ethical, Cosmetic, Generic, and others. Some of its product offerings include Alergine, Kimoxil, Loprezol, Enkasari, and Batugin among others. It generates maximum revenue from the Retail segment.
55GF Score
Get the complete analysis for ISX:KAEF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:KAEF has been successfully added to your 
